Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

Skuja,Elina; Gerina-Berzina,Aija; Hegmane,Alinta; Zvirbule,Zanete; Vecvagare,Eva; Purkalne,Gunta

doi:10.3892/mco.2018.1600

May-2018 Volume 8 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2018 Volume 8 Issue 5

Full Size Image

Article

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

Authors:
- Elina Skuja
- Aija Gerina-Berzina
- Alinta Hegmane
- Zanete Zvirbule
- Eva Vecvagare
- Gunta Purkalne
View Affiliations / Copyright

Affiliations: Clinic of Oncology, Pauls Stradins Clinical University Hospital, LV-1002 Riga, Latvia, Oncology Department University of Latvia, LV-1050 Riga, Latvia, Oncology Centre, Riga East University Hospital, LV-1079 Riga, Latvia
Pages: 699-702
|
Published online on: March 26, 2018

https://doi.org/10.3892/mco.2018.1600
Expand metrics +

Abstract

We herein describe the findings from the trifluridine/tipiracil (TAS-102) Compassionate Use program in Latvia, set up prior to marketing authorization for the management of pretreated patients with metastatic colorectal cancer (mCRC). The efficacy and safety of TAS-102 in patients with refractory mCRC were evaluated in the phase III trial RECOURSE. A previous report confirmed neutropenia and duration of previous treatment for mCRC as prognostic factors in TAS-102 users. The aim of the present study was to analyze possible prognostic factors, such as neutropenia, in TAS-102 responders. A retrospective analysis of 14 patients who received TAS-102 chemotherapy in two institutions in Latvia (Clinic of Oncology of Pauls Stradins Clinical University Hospital and Oncology Centre of Riga East University Hospital) was performed. Grade 3-4 neutropenia was observed in 28% of the patients. In patients with grade 3-4 neutropenia the median progression-free survival (mPFS) was 7 months, whereas in those without neutropenia the mPFS was 5 months [hazard ratio (HR)=0.24, P=0.033]. In 64% of the patients, the duration of previous treatment was >18 months. In patients treated for >18 months from the start of first-line mCRC treatment the mPFS was 7 months, whereas in those treated for ≤18 months from the start of first-line mCRC treatment the mPFS was 5 months (HR=0.15, P=0.029). Therefore, a longer time from mCRC diagnosis until disease progression may be used to select chemotherapy-refractory mCRC patients for TAS-102 treatment. Furthermore, severe neutropenia may be considered as a surrogate marker for predicting TAS-102 treatment outcomes.

View Figures

View References

1	Latvian cancer registry. https://www.spkc.gov.lv/upload/Veselibas%20aprupes%20statistika/Gadagramata/2015/3_sabiedribas_veseliba_2015_1.pdfMarch 20–2018
2	Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al: RECOURSE Study Group: Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med. 372:1909–1919. 2015. View Article : Google Scholar : PubMed/NCBI
3	Salvatore L, Niger M, Bellu L, Tamburini E, Garcia-Alfonso P, Amellal N, Delmas AS, Wahba M and Prager G: Compassionate use program for trifluridine/tipiracil (TAS-102) in metastatic colorectal cancer: A real-life overview. Ann Oncol. 27 suppl_6:512P2016. View Article : Google Scholar
4	Fernández CC, Roces LV, López EL, Ferreras LR, de Segura Iriarte AG and María CR: DI-064 Evaluationof tas-102 as an expanded access in refractory colorectal cancer. Eur J Hosp Pharm Sci Pract. 24:A141–A142. 2017.
5	O'Brien C, Callaghan S, Papaxoinis G, Bennett J, Lee CS, Evans RM, Iveson T, Adams R and Mullamitha S: TAS 102 in refractory metastatic colorectal cancer: UK Expanded Access Programme experience. J Clin Oncol. 35:e150432017.
6	Kotani D, Pashtoon K, Cecchini M, Shitara K, Ohtsu A, Ramanathan R, Hochster H, Grothey A and Yoshino T: PD-010 Association between chemotherapy-induced neutropenia at 1-month and overall survival in patients receiving TAS-102 for metastatic colorectal cancer. Ann Oncol. 27 suppl 2:ii1052016. View Article : Google Scholar
7	Hamauchi S, Yamazaki K, Masuishi T, Kito Y, Komori A, Tsushima T, Narita Y, Todaka A, Ishihara M, Yokota T, et al: Neutropenia as a predictive factor in metastatic colorectal cancer treated with TAS-102. Clin Colorectal Cancer. 16:51–57. 2017. View Article : Google Scholar : PubMed/NCBI
8	Kimura M, Usami E, Iwai M, Teramachi H and Yoshimura T: Severe neutropenia: A prognosticator in patients with advanced/recurrent colorectal cancerunderoral trifluridine-tipiracil (TAS-102) chemotherapy. Pharmazie. 72:49–52. 2017.PubMed/NCBI
9	Yoshino T, Mizunuma N, Yamazaki K, Nishina T, Komatsu Y, Baba H, Tsuji A, Yamaguchi K, Muro K, Sugimoto N, et al: TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 13:993–1001. 2012. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Duration of previous treatment as a prognostic factor in metastatic colorectal cancer treated with trifluridine/tipiracil

This article is mentioned in:

Abstract

Figure 1

Figure 2

Related Articles